Joleen Hubbard, MD
Dr. Joleen Hubbard is a gastrointestinal oncologist with clinical and research focus on colorectal and anal cancers. She has been the principal investigator of multiple phase I, II, and III clinical trials in gastrointestinal cancers. Her research interests also include early onset colorectal cancer, geriatric oncology, and patient reported outcomes. She previously served as a member of the NCCN colorectal/anal/small bowel guidelines panel and a member of the GI Oncology committees for the Alliance. Dr. Hubbard currently serves on the board of directors for the ACCRU clinical trials network. a member of the Society for Immunotherapy of Cancer Gastrointestinal Cancers Immunotherapy Guideline Expert Panel. In her prior role, Dr. Hubbard was the Chair of the Medical Oncology Practice at Mayo Clinic in Rochester, MN. She has started a new position as the Deputy Director for Clinical Research and Academic Affairs at the Allina Health Cancer Institute at Abbott Northwestern Hospital in Minneapolis, MN.
Financial relationships
-
Attribution:SelfType of financial relationship:OtherIneligible company:MerckTopic:Advisory BoardDate added:08/05/2023Date updated:05/23/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:BayerTopic:Advisory BoardDate added:08/05/2023Date updated:05/23/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:BeiGeneTopic:Advisory BoardDate added:08/05/2023Date updated:05/23/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:IncyteTopic:Advisory BoardDate added:08/05/2023Date updated:05/23/2024
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:MerckTopic:Research SupportDate added:08/05/2023Date updated:05/23/2024Relationship end date:07/15/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:Treos BioTopic:Research SupportDate added:08/05/2023Date updated:05/23/2024Relationship end date:07/15/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:BayerTopic:Research SupportDate added:08/05/2023Date updated:05/23/2024Relationship end date:07/15/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:IncyteTopic:Research SupportDate added:08/05/2023Date updated:05/23/2024Relationship end date:07/15/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:TriOncologyTopic:Research SupportDate added:08/05/2023Date updated:05/23/2024Relationship end date:07/15/2023
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:Seattle GeneticsTopic:Research SupportDate added:08/05/2023Date updated:05/23/2024Relationship end date:07/15/2023